Novo Nordisk Shares Face Mounting Pressure as Setbacks Pile Up
Published on 11/13/2025 at 19:10 | Redaktion boerse-global.de
Danish pharmaceutical giant Novo Nordisk finds itself navigating turbulent waters following a series of damaging developments. Investors are growing increasingly concerned as the maker of blockbuster drugs Ozempic and Wegovy confronts multiple challenges simultaneously, raising questions about the sustainability of its previous growth trajectory.
Thursday delivered a dual blow to the company’s prospects. First, research firm Morningstar substantially reduced its fair value estimate for Novo Nordisk shares, citing intensifying pricing pressures within the U.S. obesity medication market. The firm indicated that recent pricing agreements with the U.S. government would likely impact the company’s financial performance sooner than previously anticipated.
Simultaneously, biotechnology company Korro Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
